Nabriva Therapeutics plc named Jennifer Schranz as its chief medical officer to lead the clinical development and medical affairs of the Dublin-based company.

Nabriva is a clinical-stage biopharmaceutical company developing treatments for infections.

Schranz is joining the company from Shire Plc where she was in charge of the clinical development of its hereditary angioedema drug pipeline, as well as medical affairs.

"[Jennifer] brings a track record of successfully navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the lefamulin program toward a potential approval for the treatment of community-acquired bacterial pneumonia," Nabriva CEO Colin Broom said in a statement.